Share
News
-
12 December 2011 /Prices and reimbursement
Changed practice for single reimbursement for hyaluronic acid
In collaboration with the Reimbursement Committee, the Danish Medicines Agency has decided to change the practice for granting single reimbursement for hyaluronic acid. As of 15 January 2012, we will only grant single reimbursement for hyaluronic acid in exceptional circumstances and not, as we have done thus far, to all patients with osteoarthritis of the knee. In the period up until 15 January 2012, we will introduce a time limit on single reimbursement grants for hyaluronic acid to patients with knee osteoarthritis. In Denmark, hyaluronic acid is available as the two medicines Hyalgan® and Artz®, and they are used for patients with knee osteoarthritis for alleviating pain and improving the function of the knee joint.
-
15 November 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Adepend®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Adepend®. The product is neither eligible for general nor general conditional reimbursement. Adepend® is used as part of treatment of alcoholism. When we compare treatment with Adepend® with treatment with Antabuse, we assess that the price of the medicine is not reasonable relative to its therapeutic value.
-
11 November 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Xiapex®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Xiapex®. The product is neither eligible for general nor general conditional reimbursement. Xiapex® is indicated for the treatment of Dupuytren's contracture.
-
04 November 2011 /Prices and reimbursement
Comments received on the reassessment of reimbursement status of strong analgesics (opioids)
The Danish Medicines Agency has received a number of comments for the Reimbursement Committee's discussion of reimbursement status of strong analgesics (opioids). These comments were presented to the Reimbursement Committee at its meeting on 27 September 2011. The Reimbursement Committee is currently processing a recommendation.
-
01 November 2011 /Prices and reimbursement
Decision on general reimbursement for Adenuric®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Adenuric®. The product is neither eligible for general nor general conditional reimbursement. Adenuric® is used for treatment of chronic hyperuricaemia (primarily gout).
-
21 October 2011 /Prices and reimbursement
Decision on general reimbursement for Cholestagel®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Cholestagel®. The product is neither eligible for general nor general conditional reimbursement. Cholestagel® is used for treatment of elevated blood cholesterol levels.
-
12 October 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Bydureon
The Danish Medicines Agency has completed its review of an application for general reimbursement for Bydureon®. The product has been granted general reimbursement. Bydureon® is used for the treatment of type 2 diabetes in adults.
-
07 October 2011 /Prices and reimbursement
Changed reimbursement for medicines for depression and anxiety as of 5 March 2012
With effect from 5 March 2012, the reimbursement is changed for certain medicinal products for treatment of depression and anxiety (antidepressants and anxiolytics). Based on the Reimbursement Committee's recommendation, the Danish Medicines Agency has decided that in future the general rule is that treatment with inexpensive medicines (e.g. sertraline and citalopram) must be attempted before reimbursement can be granted for more expensive medicines (e.g. escitalopram, duloxetine, pregabalin and agomelatine).
-
04 October 2011 /Prices and reimbursement
The reimbursement for glucosamine is removed on 28 November 2011
The Reimbursement Committee and the Danish Medicines Agency have reassessed the reimbursement status of glucosamine-containing medicines. We have decided to remove the reimbursement for these over-the-counter medicines on 28 November 2011. Glucosamine is used for the alleviation of painful osteoarthritis.
-
21 September 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Trajenta®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Trajenta®. The product has been granted general reimbursement.
-
20 September 2011 /Prices and reimbursement
Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines
The Reimbursement Committee’s recommendation on the future reimbursement status of glucosamine-containing medicines was open for consultation until 8 August 2011. The Danish Medicines Agency received 4 consultation responses.
-
20 September 2011 /Prices and reimbursement
Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)
The Reimbursement Committee’s recommendation on the future reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B was open for consultation until 15 August 2011. The Danish Medicines Agency received 9 consultation responses.
-
26 August 2011 /Prices and reimbursement
Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine
On 15 August 2011, the Danish Medicines Agency announced that we would begin reassessing the reimbursement status of medicines in ATC group N02A, opioids. The Reimbursement Committee opened its preliminary discussions at its meeting on 23 August 2011 and recommended to include the opioids methadone (N07BC02) and codeine (R05DA04), also used in pain management, in the reassessment of reimbursement status of medicinal products in ATC group N02A.
-
15 August 2011 /Prices and reimbursement
Reassessment of reimbursement status of strong analgesics (opioids)
On 22 December 2009, the Danish Medicines Agency announced that it would begin reassessing the reimbursement status of medicines in ATC group N (nervous system) starting with the ATC subgroup N06A (antidepressants) and then N02A (opioids). The Reimbursement Committee is having the initial discussions of the opioids at its meeting on 23 August 2011.
-
12 August 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Pradaxa®
The Danish Medicines Agency has completed its review of an application for continued general reimbursement for Pradaxa®. The product maintains general reimbursement. Pradaxa® is now also authorised for prevention of apoplexy (stroke) and systemic embolism in patients with atrial fibrillation.
-
05 July 2011 /Prices and reimbursement
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)
At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group C01 – cardiac therapy. These medicines are used for the treatment of cardiac arrhythmia (e.g. atrial fibrillation) and heart cramps (angina pectoris).
-
05 July 2011 /Prices and reimbursement
Guiding criteria for single reimbursement of cardiovascular medicines and drugs for acid-related disorders
In collaboration with the Reimbursement Committee, the Danish Medicines Agency has prepared guiding criteria for single reimbursement of angiotensin II antagonists and the renin inhibitor aliskiren (cardiovascular medicines) and the proton pump inhibitors esomeprazole og rabeprazole (drugs for acid-related disorders).
-
05 July 2011 /Prices and reimbursement
Development in the consumption of cardiovascular medicines from December 2008 to March 2011
The Danish Medicines Agency monitors the trends in consumption of cardiovascular medicines (blood pressure medicines) in connection with the reimbursement changes for cardiovascular medicines of 13 July 2009 and 15 November 2010.
-
01 July 2011 /Prices and reimbursement
Decision on general reimbursement for Targin®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Targin®. The product is eligible for general conditional reimbursement from 11 July 2011.
-
01 July 2011 /Prices and reimbursement
Decision on general reimbursement for Eliquis®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Eliquis®. The product is eligible for general reimbursement from 11 July 2011.
